Abstract:Objective: All-trans-retinoic acid (ATRA), chemotherapy, and arsenic trioxide (As2O3) have been found to be effective in the treatment of acute promyelocytic leukemia (APL). Here we present a single institutional retrospective study with longterm follow-up to better define the prognostic factors and a rationale for the use of ATRA, chemotherapy, and As2O3 in the treatment of newly diagnosed and relapsed APL patients.Patients and methods: Newly diagnosed patients with APL entering complete remission were followed up for 3 to 95 months (n = 120). Univariate and multivariate analyses were performed to identify potential prognostic factors, including age and sex; initial white blood cell (WBC) count and peak WBC level of hyperleukocytosis during induction therapy; dose of ATRA in induction; days from induction therapy to remission; postremission therapy, type of PML-RAR alpha isoform; and follow-up of reverse transcription-polymerase chain reaction (RT-PCR).Results: The median relapse-free survival (RFS) was 26 months, and median overall survival (OS) was still not reached. The estimated 5-year RFS and OS were 34.0% +/- 6.0% and 52.5% +/- 7.9%, respectively. Initial WBC count greater than or equal to 20 X 10(9)/l), peak level of WBC during induction: and type of postremission therapy were significantly related to survival. Our multivariate study showed that only peak level of WBC count during induction therapy and type of postremission therapy were associated with RFS and that initial WBC count was associated with OS. In relapsed patients, As2O3 was very effective and remained as the most important factor for their entering remission and survival after relapse.Conclusion: Through this retrospective study with long term follow-up, some conclusions can be drawn: I) Low-dose ATRA is as effective as the standard dose in terms of survival: 2) Initial and peak levels of WBC count during induction therapy are associated with survival: 3) A combination of chemotherapy and ATRA is better than chemotherapy or ATRA alone as postremission therapy, 4) Patients with the long form of PML-RAR alpha tend to have a more favorable OS but not RFS when compared with patients with the short form: 5) Persistent negative RT-PCR in remission is associated with favorable RFS and OS: 6) As2O3 is an effective agent for relapsed patients. (C) 1999 The Japanese Society of Hematology.

Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Studies on Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients.

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Ape) .2. Clinical Efficacy And Pharmacokinetics In Relapsed Patients

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Progress on the Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide

Arsenic trioxide, a therapeutic agent for APL.

Arsenic Trioxide Replacing or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].

Studies on the Clinical Efficacy and Pharmacokinetics of Low-Dose Arsenic Trioxide in the Treatment of Relapsed Acute Promyelocytic Leukemia: a Comparison with Conventional Dosage.

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Apl) .1. As2o3 Exerts Dose-Dependent Dual Effects On Apl Cells

Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.

[Pharmacokinetics of Intravenous Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia].

All-trans Retinoic Acid/as 2 O 3 Combination Yields a High Quality Remission and Survival in Newly Diagnosed Acute Promyelocytic Leukemia

Long-Term Survival And Prognostic Study In Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid, Chemotherapy, And As2o3: An Experience Of 120 Patients At A Single Institution

Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia